FDA clears expansion of CeloNova’s nano-coated coronary stent trial

CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding.

The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA clears expansion of CeloNova’s nano-coated coronary stent trial appeared first on MassDevice.

from MassDevice http://ift.tt/2hcp4DB